The Manufacturers Life Insurance Company Takes Position in Tempus AI, Inc. (NASDAQ:TEM)

The Manufacturers Life Insurance Company acquired a new position in Tempus AI, Inc. (NASDAQ:TEM) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 27,024 shares of the company’s stock, valued at approximately $946,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Davidson Kempner Capital Management LP acquired a new stake in shares of Tempus AI during the 2nd quarter worth approximately $2,271,000. NEA Management Company LLC acquired a new stake in Tempus AI during the 2nd quarter worth $160,048,000. Federated Hermes Inc. acquired a new stake in Tempus AI during the 2nd quarter worth $19,886,000. Dragoneer Investment Group LLC bought a new stake in shares of Tempus AI during the 2nd quarter valued at $1,750,000. Finally, Lingotto Investment Management LLP bought a new position in shares of Tempus AI in the 2nd quarter worth $32,685,000.

Tempus AI Stock Up 6.2 %

TEM opened at $48.82 on Monday. The company has a current ratio of 3.70, a quick ratio of 3.52 and a debt-to-equity ratio of 4.50. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $77.00. The company has a fifty day moving average of $51.42.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($6.77) EPS for the quarter, missing analysts’ consensus estimates of ($4.41) by ($2.36). The firm had revenue of $165.97 million during the quarter, compared to the consensus estimate of $159.10 million. On average, research analysts predict that Tempus AI, Inc. will post -6.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on TEM shares. Longbow Research started coverage on Tempus AI in a research note on Tuesday, July 9th. They issued a “buy” rating and a $48.00 target price on the stock. William Blair began coverage on shares of Tempus AI in a report on Tuesday, July 9th. They set an “outperform” rating for the company. TD Cowen started coverage on shares of Tempus AI in a report on Tuesday, July 9th. They issued a “buy” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on shares of Tempus AI from $42.00 to $47.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Piper Sandler initiated coverage on shares of Tempus AI in a research report on Monday, August 12th. They issued a “neutral” rating and a $40.00 price objective for the company. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.67.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.